JP2021527713A5 - - Google Patents

Info

Publication number
JP2021527713A5
JP2021527713A5 JP2021519532A JP2021519532A JP2021527713A5 JP 2021527713 A5 JP2021527713 A5 JP 2021527713A5 JP 2021519532 A JP2021519532 A JP 2021519532A JP 2021519532 A JP2021519532 A JP 2021519532A JP 2021527713 A5 JP2021527713 A5 JP 2021527713A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
markers
proliferative
Prior art date
Application number
JP2021519532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527713A (ja
JPWO2019241802A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037559 external-priority patent/WO2019241802A2/en
Publication of JP2021527713A publication Critical patent/JP2021527713A/ja
Publication of JP2021527713A5 publication Critical patent/JP2021527713A5/ja
Publication of JPWO2019241802A5 publication Critical patent/JPWO2019241802A5/ja
Priority to JP2024109073A priority Critical patent/JP2024153667A/ja
Pending legal-status Critical Current

Links

JP2021519532A 2018-06-15 2019-06-17 増殖性細胞を抑制する方法 Pending JP2021527713A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024109073A JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685866P 2018-06-15 2018-06-15
US62/685,866 2018-06-15
PCT/US2019/037559 WO2019241802A2 (en) 2018-06-15 2019-06-17 Methods of inhibiting proliferative cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024109073A Division JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Publications (3)

Publication Number Publication Date
JP2021527713A JP2021527713A (ja) 2021-10-14
JP2021527713A5 true JP2021527713A5 (https=) 2022-06-27
JPWO2019241802A5 JPWO2019241802A5 (https=) 2022-06-27

Family

ID=67138135

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519532A Pending JP2021527713A (ja) 2018-06-15 2019-06-17 増殖性細胞を抑制する方法
JP2024109073A Pending JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024109073A Pending JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Country Status (4)

Country Link
US (1) US20210371855A1 (https=)
EP (1) EP3806850A2 (https=)
JP (2) JP2021527713A (https=)
WO (1) WO2019241802A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013120A (es) 2018-06-04 2021-07-21 Broad Inst Inc Tratamiento terapéutico de cánceres de microsatélites inestables.
JP7714162B6 (ja) * 2018-12-03 2025-09-08 タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法
AR122534A1 (es) 2020-06-03 2022-09-21 Triplet Therapeutics Inc Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
JP2024508841A (ja) * 2021-02-25 2024-02-28 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ プログラム可能なタンパク質分解のための化合物及び疾患処置のための使用方法
JP7753397B2 (ja) * 2021-05-26 2025-10-14 ノバルティス アーゲー ウェルナー症候群ＲｅｃＱヘリカーゼ（ＷＲＮ）の阻害に関連する疾患を治療するためのトリアゾロ－ピリミジン類似体
WO2023062575A1 (en) * 2021-10-14 2023-04-20 Ideaya Biosciences, Inc. Cyclic vinyl sulfone compounds as wrn inhibitors
KR20250034120A (ko) * 2022-07-06 2025-03-10 비비디온 테라퓨틱스, 인코포레이티드 Wrn 헬리케이스 억제제를 포함하는 약제학적 조성물
TW202421158A (zh) 2022-11-18 2024-06-01 瑞士商諾華公司 藥物組合及其用途
WO2024140597A1 (zh) * 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Wrn解旋酶抑制剂
CN120603834A (zh) * 2023-01-18 2025-09-05 成都微芯药业有限公司 双杂环wrn抑制剂、其制备方法及其应用
WO2024153244A1 (zh) * 2023-01-20 2024-07-25 南京再明医药有限公司 含氮类化合物
WO2024215923A2 (en) * 2023-04-11 2024-10-17 Nimbus Wadjet, Inc. Cyclic vinyl sulfone wrn inhibitors
WO2024235844A1 (en) * 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
TW202510857A (zh) * 2023-06-01 2025-03-16 英商葛蘭素史密斯克藍智慧財產權有限公司 化合物及其用途
WO2025026382A1 (zh) * 2023-08-01 2025-02-06 海思科医药集团股份有限公司 一种氧代三并环类衍生物及其在医药上的应用
WO2025106693A1 (en) * 2023-11-16 2025-05-22 Eikon Therapeutics, Inc. Methods and compositions for treating cancers with high microsatellite instability levels
WO2025131978A1 (en) * 2023-12-20 2025-06-26 Nerviano Medical Sciences S.R.L. Drug-linker reagents for conjugation
WO2025237361A1 (zh) * 2024-05-16 2025-11-20 海思科医药集团股份有限公司 一种氧代三并环类衍生物及其在医药上的应用
WO2025239377A1 (ja) * 2024-05-16 2025-11-20 株式会社ジーンケア研究所 ＷＲＮヘリカーゼ遺伝子を標的とするｓｉＲＮＡ
WO2025252190A1 (en) * 2024-06-07 2025-12-11 Cullgen Inc. Targeted degraders of werner syndrome recq helicase

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372772B1 (en) * 1997-08-01 2002-04-16 Prolx Pharmaceuticals Corporation Inhibitors of redox signaling and methods of using same
WO2002024692A1 (en) * 2000-09-20 2002-03-28 Karolinska Innovations Ab 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
US6448080B1 (en) * 2001-02-23 2002-09-10 Isis Pharmaceuticals, Inc. Antisense modulation of WRN expression
US7659278B2 (en) * 2002-02-21 2010-02-09 Aprea Ab Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
EP1761629A2 (en) * 2004-05-19 2007-03-14 Trustees Of Boston University Modulation of wrn-mediated telomere-initiated cell signaling
WO2011014825A2 (en) * 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiangiogenic small molecules and methods of use
JP5762103B2 (ja) * 2011-04-13 2015-08-12 国立大学法人滋賀医科大学 頭頸部癌及び食道癌用抗癌剤及び増強剤
EP2836606B1 (en) * 2012-04-10 2021-12-29 Vib Vzw Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the dna base excision repair pathway
CA2951816A1 (en) * 2013-06-12 2014-12-18 Oncoimmunin, Inc. Systemic in vivo delivery of oligonucleotides
US20190185849A1 (en) 2016-06-29 2019-06-20 Crispr Therapeutics Ag Compositions and methods for gene editing
US11530413B2 (en) * 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
MX2020013120A (es) * 2018-06-04 2021-07-21 Broad Inst Inc Tratamiento terapéutico de cánceres de microsatélites inestables.
JP7753397B2 (ja) * 2021-05-26 2025-10-14 ノバルティス アーゲー ウェルナー症候群ＲｅｃＱヘリカーゼ（ＷＲＮ）の阻害に関連する疾患を治療するためのトリアゾロ－ピリミジン類似体

Similar Documents

Publication Publication Date Title
JP2021527713A5 (https=)
JPWO2019241802A5 (https=)
Di Carlo et al. State of the art CRISPR-based strategies for cancer diagnostics and treatment
Dobbelstein et al. Targeting tumour-supportive cellular machineries in anticancer drug development
Schneider et al. Tissue-specific tumorigenesis: context matters
Moffat et al. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl) methyl] amino} bicyclo [3.1. 0] hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor
EP3691620B1 (en) P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
JP2021526132A5 (https=)
Hassan et al. MicroRNA-122 mimic/microRNA-221 inhibitor combination as a novel therapeutic tool against hepatocellular carcinoma
EP3655004A2 (en) Compositions and methods to treat cancer
JPWO2019213516A5 (https=)
Li et al. Epigenetic alterations in osteosarcoma: promising targets
JP2020522508A5 (https=)
JP2020516693A5 (https=)
Jaiswal et al. DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer
Serda et al. Glycofullerenes as non-receptor tyrosine kinase inhibitors-towards better nanotherapeutics for pancreatic cancer treatment
Couto et al. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines
Nabilsi et al. Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter
Chen et al. The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells
JP2011524355A5 (https=)
JP2021514979A5 (https=)
US9801854B1 (en) Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer
JP2016519084A5 (https=)
CN115803031A (zh) 用于癌症治疗的贝伐非尼
Sanjuvikasini et al. CRISPR/Cas9 Technology: Making Possibilities against Breast Cancer